CRISPR effector system based diagnostics

US11104937B2 · kind B2 · utility

Assignees

• The Broad Institute, Inc. · US
• Massachusetts Institute of Technology · US
• President and Fellows of Harvard College · US
• The General Hospital Corporation · US

Inventors

• Omar Abudayyeh · Cambridge, US
• James J. Collins · Watertown, US
• Jonathan Gootenberg · Cambridge, US
• Feng Zhang · Cambridge, US
• Eric S. Lander · Cambridge, US
• Roby Bhattacharyya · Cambridge, US
• Deborah Hung · Cambridge, US

Key dates

• Filing date: Mar 15, 2018
• Grant date: Aug 31, 2021
• Expiry date: Feb 16, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/3519
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect broth DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.